Zentalis Pharmaceuticals (ZNTL) Net Equity Issued and Repurchased (2019 - 2022)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Net Equity Issued and Repurchased of $48.6 million for Q4 2022, up 398.72% year-over-year from $9.8 million in Q4 2021, and down 73.62% quarter-over-quarter from $184.3 million in Q2 2022.
Zentalis Pharmaceuticals (ZNTL) Net Equity Issued and Repurchased (2019 - 2022) Analysis & Trends
Zentalis Pharmaceuticals' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $48.6 million for Q4 2022.
- In Q4 2022, Net Equity Issued and Repurchased rose 398.72% year-over-year to $48.6 million; the TTM figure through Sep 2024 stood at $48.6 million (down 79.12% YoY), while the FY2025 annual figure was $5.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q4 2022 stood at $48.6 million, down from $184.3 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $184.3 million in Q2 2022, with the low at -$141.7 million in Q4 2020.
- The 4-year median for Net Equity Issued and Repurchased is $65.3 million (2019), against an average of $62.6 million.
- The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased climbed 14.51% in 2021, then soared 398.72% in 2022.
- Zentalis Pharmaceuticals' Net Equity Issued and Repurchased stood at $81.9 million in 2019, then slumped by 272.98% to -$141.7 million in 2020, then surged by 106.88% to $9.8 million in 2021, then jumped by 398.72% to $48.6 million in 2022.
- Business Quant data shows ZNTL's Net Equity Issued and Repurchased at $48.6 million in Q4 2022, $184.3 million in Q2 2022, and $9.8 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 48.63 Mn |
| Dec 31, 2022 | 48.63 Mn |
| Jun 30, 2022 | 184.30 Mn |
| Jun 30, 2022 | 184.30 Mn |
| Dec 31, 2021 | 9.75 Mn |
| Dec 31, 2021 | 9.75 Mn |
| Sep 30, 2021 | 162.22 Mn |
| Sep 30, 2021 | 162.22 Mn |
| Dec 31, 2020 | -141.67 Mn |
| Dec 31, 2020 | -141.67 Mn |
| Sep 30, 2020 | 141.67 Mn |
| Sep 30, 2020 | 141.67 Mn |
| Mar 31, 2020 | 14.23 Mn |
| Mar 31, 2020 | 14.23 Mn |
| Sep 30, 2019 | 81.90 Mn |
| Sep 30, 2019 | 81.90 Mn |